CSIMarket Company Name, Ticker, Customers, else..
 
Kalaris Therapeutics Inc   (NASDAQ: KLRS)
 

Kalaris Therapeutics Inc's Suppliers Performance

KLRS's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
KLRS Costs vs Sales of Suppliers Growth

• More on KLRS Suppliers






Kalaris Therapeutics Inc's Comment on Supply Chain


The company utilizes contract manufacturers for the production of its product candidate for clinical trials and potential commercial manufacturing. The primary contract manufacturers are STC Biologics, Inc. and Sharp Sterile Manufacturing (formerly Berkshire Sterile Manufacturing Inc.). KBI Biopharma, located in North Carolina, acts as the Contract Development and Manufacturing Organization (CDMO) for future clinical and commercial supply manufacturing of the TH103 drug substance. The company is currently selecting a CDMO partner for manufacturing the TH103 drug product. TH103 is produced through biological manufacturing processes involving Chinese hamster ovary K1 cells and recombinant DNA technology. The company depends on third parties for packaging, labeling, storage, and distribution of TH103 and intends to maintain this reliance if marketing approval is obtained. This approach supports maintaining an efficient infrastructure while focusing resources on clinical development and commercialization.

Kalaris Therapeutics Inc's Comment on Supply Chain


The company utilizes contract manufacturers for the production of its product candidate for clinical trials and potential commercial manufacturing. The primary contract manufacturers are STC Biologics, Inc. and Sharp Sterile Manufacturing (formerly Berkshire Sterile Manufacturing Inc.). KBI Biopharma, located in North Carolina, acts as the Contract Development and Manufacturing Organization (CDMO) for future clinical and commercial supply manufacturing of the TH103 drug substance. The company is currently selecting a CDMO partner for manufacturing the TH103 drug product. TH103 is produced through biological manufacturing processes involving Chinese hamster ovary K1 cells and recombinant DNA technology. The company depends on third parties for packaging, labeling, storage, and distribution of TH103 and intends to maintain this reliance if marketing approval is obtained. This approach supports maintaining an efficient infrastructure while focusing resources on clinical development and commercialization.







KLRS's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Kalaris Therapeutics Inc 69.01 0.00 -44.26 20
SUBTOTAL 0.00 0.00 0.00 -


Sources: Kalaris Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Kalaris Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.